



TransEnterix Announces LSU Health Completes Purchase of Senhance Surgical System

May 31, 2018

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 31, 2018-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that LSU Health completed the purchase of the Company's Senhance™Surgical System. The Senhance has been installed at University Medical Center New Orleans (UMC New Orleans).

UMC New Orleans is home to the Reverend Avery C. Alexander Academic Research Hospital, and is an academic medical center in partnership with LSU Health New Orleans, Tulane University School of Medicine, and other local colleges and universities. UMC New Orleans will be a center for clinical excellence utilizing the Senhance Surgical System in general, colorectal and gynecologic surgery.

The Senhance Surgical System represents an innovative technology designed to assist surgeons in performing minimally invasive surgery. While seated comfortably at a console, the surgeon uses multiple robotic arms to control small surgical instruments with robotic precision while at the same time moving a small scope that tracks the eye movement of the surgeon. The Senhance is the first surgical robotic system to offer the security of haptic force feedback that allows surgeons to feel the forces the instruments generate when handling delicate tissue.

"We are pleased that LSU Health New Orleans is beginning its digital laparoscopy program using the Senhance Surgical system," said Todd M. Pope, President and CEO at TransEnterix. "Our system is designed to support responsible economics for the hospital, and we look forward to partnering with the surgeons at UMC New Orleans to advance patient care in ways that matter in today's value-based healthcare landscape."

"LSU Health New Orleans and University Medical Center New Orleans see the Senhance Surgical System as an important and necessary advance in surgical care," said Dr. Guy Orangio FACS, FASCRS, Chief Section of Colorectal Surgery at LSU Health New Orleans, and President of the American Society of Colon and Rectal Surgeons. "This new robotic system brings enabling technology with haptic feedback and innovative surgeon camera control while minimizing costs and maintaining existing efficiencies."

"Patients are seeking minimally invasive options that utilize the most advanced technology to treat gynecologic conditions," said Dr. Lisa M. Peacock, Chairperson of the Department of Obstetrics and Gynecology, and Section Head and Program Director of Female Pelvic Medicine and Reconstructive Surgery at LSU Health New Orleans. "As an academic medical center, we believe this new robotic surgical platform will play an important role in our continued leadership in surgical teaching, research, and providing excellent patient care."

On May 29, 2018, TransEnterix announced that it received FDA 510(k) clearance for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) procedures, doubling its total addressable market in the U.S. to over three million annual procedures. In the U.S., Senhance is now cleared for laparoscopic colorectal, gynecologic, inguinal hernia and cholecystectomy surgery.

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU and select other countries. For more information, visit www.transenterix.com.

About University Medical Center New Orleans

Opened in August 2015, University Medical Center New Orleans is the academic medical center of LCMC Health, a Louisiana-based, not-for-profit health system. UMC New Orleans serves as a key partner of LSU Health Science Center New Orleans, Tulane University School of Medicine and other academic institutions. UMC is home to the Rev. Avery C. Alexander Academic Research Hospital, named in honor of the respected Civil Rights and community leader who served in the Louisiana Legislature for more than 20 years.

Forward-Looking Statements

This press release includes statements relating to the Senhance Surgical System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether TransEnterix's partnering with the surgeons at UMC New Orleans will advance patient care in ways that matter in today's value-based healthcare landscape and whether the Senhance Surgical Robotic System will play an important role in UMC New Orleans' continued leadership in surgical teaching, research, and providing excellent patient care. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 8, 2018 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180531005308/en/>

Source: TransEnterix, Inc.

For TransEnterix, Inc.

Investor Contact:

Mark Klausner, +1 443-213-0501

invest@transenterix.com

or

Media Contact:

Joanna Rice, + 1 951-751-1858

joanna@greymattermarketing.com